Anebulo Pharmaceuticals (NASDAQ:ANEB) vs. Oric Pharmaceuticals (NASDAQ:ORIC) Financial Analysis

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Valuation & Earnings

This table compares Anebulo Pharmaceuticals and Oric Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48 million	($0.19)	-1.58
Oric Pharmaceuticals	N/A	N/A	-$129.47 million	($1.35)	-10.09

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Anebulo Pharmaceuticals and Oric Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1	0	0	0	1.00
Oric Pharmaceuticals	1	2	13	0	2.75

Oric Pharmaceuticals has a consensus target price of $19.45, suggesting a potential upside of 42.84%. Given Oric Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Anebulo Pharmaceuticals.

Risk & Volatility

Anebulo Pharmaceuticals has a beta of -1.82, suggesting that its stock price is 282% less volatile than the S&P 500. Comparatively, Oric Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Insider & Institutional Ownership

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Anebulo Pharmaceuticals and Oric Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Summary

Oric Pharmaceuticals beats Anebulo Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.